Show simple item record

dc.contributor.authorCurcean, A
dc.contributor.authorCurcean, S
dc.contributor.authorRescigno, P
dc.contributor.authorDafydd, DA
dc.contributor.authorTree, A
dc.contributor.authorReid, A
dc.contributor.authorKoh, D-M
dc.contributor.authorSohaib, A
dc.contributor.authorTunariu, N
dc.contributor.authorShur, J
dc.coverage.spatialEngland
dc.date.accessioned2022-06-16T13:56:31Z
dc.date.available2022-06-16T13:56:31Z
dc.date.issued2022-02-01
dc.identifierS0009-9260(21)00430-X
dc.identifier.citationClinical Radiology, 2022, 77 (2), pp. 88 - 95
dc.identifier.issn0009-9260
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5182
dc.identifier.eissn1365-229X
dc.identifier.doi10.1016/j.crad.2021.09.005
dc.description.abstractThe pattern of metastases in prostate cancer (PC) is evolving. Increased use of imaging, newer imaging techniques with higher sensitivity for disease detection and patients receiving multiple lines of novel therapies with increased life expectancy are likely to be contributory. Awareness of metastatic disease patterns improves early diagnosis, accurate staging, and initiation of appropriate therapy, and can inform prognostic information and anticipate potential disease complications. The aim of this review is to document the spectrum of metastases in PC including emerging and unusual patterns, and to highlight the role of novel imaging including prostate-specific membrane antigen (PSMA)-positron-emission tomography (PET) and whole-body magnetic resonance imaging (WB-MRI) to improve diagnostic and response assessment accuracy.
dc.formatPrint-Electronic
dc.format.extent88 - 95
dc.languageeng
dc.language.isoeng
dc.publisherW B SAUNDERS CO LTD
dc.relation.ispartofClinical Radiology
dc.subjectHumans
dc.subjectMagnetic Resonance Imaging
dc.subjectMale
dc.subjectPositron-Emission Tomography
dc.subjectProstate
dc.subjectProstatic Neoplasms
dc.subjectWhole Body Imaging
dc.titleImaging features of the evolving patterns of metastatic prostate cancer.
dc.typeJournal Article
dcterms.dateAccepted2021-09-02
dc.date.updated2022-06-16T10:35:17Z
rioxxterms.versionofrecord10.1016/j.crad.2021.09.005
rioxxterms.licenseref.startdate2022-02-01
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34598790
pubs.issue2
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume77
icr.researchteamPrCa Targeted Therapy
icr.researchteamRMH Honorary Faculty
dc.contributor.icrauthorRescigno, Pasquale


Files in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record